In his new role, Benecchi will lead Sage's global commercial efforts across all Sage programs, new product planning, strategy, and competitive intelligence.
Benecchi will work in collaboration with internal partners to create a shared, mission-driven, launch vision that reflects the input the company receives from external stakeholders.
Among his responsibilities will be to ensure smooth working relationships with Sage's partners and an integrated commercialization plan for zuranolone a once-daily, two-week therapy in Phase 3 clinical development for the treatment of major depressive disorder and postpartum depression.
Benecchi will also lead commercialization strategies across the company's leading portfolio of treatments for brain health disorders.
Chris Benecchi joins Sage from Alexion, where he served as vice president, Global Head of Commercial Excellence.
Previously, he spent eight years at UCB in commercial roles of increasing responsibility including Global Launch Head, Commercial and Medical Affairs, Immunology and Global Commercial Strategy Lead, Immunology.
He began his career in sales at J and J and held sales leadership and senior marketing roles at Takeda as well. Benecchi received an MBA from Duke University and a BA from Colby College.
Sage Therapeutics is a biopharmaceutical company focused on developing novel therapies for patients with debilitating disorders of the brain.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer